trabectedin,rain-32
pharmamar,valeo pharmaceutical,otsuka,rain therapuetics
['mantra', 'rain_thera']
this year at #asco22, we are presenting three posters on our lead candidate, an oral mdm2 inhibitor. the presentations, which are taking place on sunday, june 5, highlight preclinical data and our mantra &amp; mantra-2 trials in progress. learn more here: 
A San Francisco Bay Area-based biotechnology company focused on developing targeted therapies for patients with cancer